Procter & Gamble shares have sunk to levels not seen since early 2020, reflecting widespread investor pessimism. The stock is now trading approximately 20% below its two-hundred-day moving average, a technical setup that historically precedes multi-year outperformance. With consensus earnings per share guidance for fiscal 2026 set at a range of 6.83 to 7.09 and an average analyst forecast of 6.91, the market is pricing in flat growth. Yet even this tepid outcome would sustain a return on equity above 30% and net margins near 19%, underpinning nearly $22.2 billion in quarterly revenue and a 2.8% dividend yield. At current levels, investors are essentially buying a world-class cash flow generator at a significant discount to fair value.

In the third quarter, GDS Wealth Management boosted its Procter & Gamble holding by 20.9%, acquiring an additional 14,060 shares to bring its total position to 81,190 shares, valued at approximately $12.48 million. Several other asset managers also adjusted their exposure: BAM Wealth initiated a $678,000 stake, Acorn Wealth Advisors added 173 shares (a 4.5% increase), PFG Investments purchased 870 shares (1.6%), Symphony Financial bought 257 shares (1.9%), and Inlet Private Wealth added 172 shares (1.6%). Collectively, hedge funds and institutions account for 65.8% of the company’s outstanding shares, reflecting broad confidence in P&G’s durable cash flows despite cyclical headwinds.

On January 22, Procter & Gamble reported 1.88 dollars of earnings per share for the quarter, surpassing consensus by 0.02 dollars and matching the prior-year profit level. Revenue rose 1.5% year-over-year to 22.21 billion dollars, narrowly trailing forecasts of 22.36 billion. The company reaffirmed full-year guidance of 6.830 to 7.090 dollars in EPS, implying mid-single-digit growth. Meanwhile, the board declared a quarterly dividend of 1.0568 dollars per share to be paid on February 17, maintaining a payout ratio of 62.7% and delivering a 2.8% yield. With free cash flow conversion above 90%, P&G’s dividend appears secure even under conservative growth scenarios.

Over the past week, four major research firms raised their outlook on Procter & Gamble. JPMorgan Chase shifted from Neutral to Overweight and lifted its twelve-month target from 157 dollars to 165 dollars. UBS increased its price objective from 161 dollars to 170 dollars, reaffirming a Buy rating. Wells Fargo also moved to Overweight, boosting its target from 158 dollars to 165 dollars. Conversely, one firm trimmed its forecast from 185 dollars to 175 dollars but maintained an Outperform recommendation. Overall, 14 analysts rate the company a Buy and eight assign a Hold, resulting in a consensus of Moderate Buy with an average target of 166.70 dollars.